Uncategorized
A PureTech startup banks $180M for a new IPF drug
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche’s Esbriet.
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche’s Esbriet.